I confess to taking immense pleasure in watching two of the biggest villains in the health care spending conundrum bash each other over their business practices. The 340B program was originally designed to allow certain providers to offer less-expensive drugs to low-income patients. Hospitals have grossly abused the program and made immense profits in doing so. Drug companies aren’t happy because this means they are getting less money for more prescriptions and missing opportunities to get their usual immense profit margins. So tragic for both industries to face the potential that Congress or CMS may rein in the program. But maybe consumers will get some relief. Here is the latest research salvo, again from the drug manufacturers, using hired gun Berkeley Research Group. (BRG Report) The analysis looked at spending trends before and after a hospital enrolls in the 340B program. 379 hospitals enrolled in the program during the study period from January 2009 to January 2016. Drug spending was tracked at a patient level. The average per patient drug spend increased about 32% after the hospital switched to the program, compared to a spending increase of 13% at hospitals which did not enroll in the program. Looking just at patients in the first year of the hospital’s participation, the spending increase was 21% compared to 4.7% at the control group. There are differences among hospitals in the program, some appear to be better at figuring out how to maximize their profits by taking the low price drugs and using them for patients with good insurance coverage. 63% of hospitals in the program had a per patient drug spending growth rate at least 2 percentage points higher than that for the control group of hospitals. This analysis just confirms that many hospitals have used the 340B program to maximize profits, not lower costs for patients and third-party payers. But again, hard to feel sorry for drug companies, especially after the most recent revelations about their cancer drug profits, reported here earlier this week.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Now here is a tale from the glory days of epidemic investing, as the Feds pumped trillions into the economy and a lot of it went to investing, some to...
January 10, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace